RPRX vs XLF
Royalty Pharma Plc (RPRX) versus XLF (XLF) — a side-by-side from cached financials, not a winner call.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
XLF (XLF) common stock.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
XLF does not have a complete income-statement cache yet.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. XLF currently screens at market cap $0.
Not investment advice. Open the RPRX and XLF stock pages for the full models.
Not investment advice.